@article{oai:u-ryukyu.repo.nii.ac.jp:02011336,
 author = {浜田, 聡 and 宮下, 倫江 and 山本, 雄一 and 宮本, 二郎 and 屋冝, 孟 and 大城, 登喜子 and 浜田, 有為子 and 喜友名, しのぶ and 新垣, 真弓 and 百名, 伸之 and Hamada, Satoru and Miyashita, Michie and Yamamoto, Yuichi and Miyamoto, Jiro and Yagi, Takeshi and Oshiro, Tokiko and Hamada, Yuiko and Kiyuna, Shinobu and Arakaki, Mayumi and Hyakuna, Nobuyuki},
 issue = {5},
 journal = {日本小児血液・がん学会雑誌},
 month = {},
 note = {Sclerodermatous GVHD is a late effect of hematopoietic stem cell transplantation, which results in the impairment of the quality of a ­survivor’s life, and is difficult to manage. Most cases are often steroid-refractory and steroid-dependent sclerodermatous GVHD, and secondary treatment sometimes has limited efficacy. We performed a retrospective study on four sclerodermatous GVHD patients presenting severe joint contracture treated with narrow-band ultraviolet B (NB-UVB) from July 2012 to May 2015. All the patients had sclerodermatous grade 2 or higher according to the National Institutes of Health (NIH) grading, and showed less than 70% in the performance scale (PS). Three patients received steroid therapy, namely, two patients with steroid-refractory and one patient with steroiddependent sclerodermatous GVHD. The remaining patient had a high possibility of acute myeloid leukemia relapse, favoring less immuno­suppressant administration. We evaluated the responses of the patients with a photographic range of motion according to the NIH therapeutic response criteria. The observation period after irradiation was 718 days (range: 368–1039 days). A mean cumulative dose of 75 J/cm^2  (range: 51–221 J/cm^2 ) was applied in a mean number of 69 irradiations (range 53–159). All the patients showed improvement in the range of motion. The PS score was improved from a mean of 40% (pretreatment) to 75% (post-treatment). In western countries, extracorporeal photopheresis (ECP) is the mainstream secondary treatment for sclerodermatous GVHD, and its clinical trial is in progress in Japan. ECP is a promising treatment; however, there are a few problems, such as its high cost and facility accessibility in local areas. Therefore, NB-UVB can be an encouraging alternative to ECP for sclerodermatous GVHD., 論文},
 pages = {453--458},
 title = {強皮症様皮膚硬化を認める難治性慢性GVHDに対し短波長紫外線照射が奏功した4症例},
 volume = {53},
 year = {2016}
}